argenx SE – (NASDAQ:ARGX) Receives $151.22 Consensus PT from Brokerages

Shares of argenx SE – (NASDAQ:ARGX) have been given an average rating of “Buy” by the fourteen analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $154.11.

Several equities research analysts have commented on the stock. Stifel Nicolaus reissued a “buy” rating and set a $154.00 price target on shares of argenx in a research report on Thursday. Piper Jaffray Companies boosted their price target on shares of argenx from $161.00 to $182.00 and gave the stock an “overweight” rating in a research report on Thursday, May 23rd. ValuEngine lowered shares of argenx from a “buy” rating to a “hold” rating in a research note on Thursday. Wedbush boosted their price objective on shares of argenx from $144.00 to $170.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Robert W. Baird assumed coverage on shares of argenx in a research note on Thursday, June 27th. They set an “outperform” rating and a $170.00 price objective on the stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of argenx in the fourth quarter worth about $23,999,000. Dimensional Fund Advisors LP lifted its stake in shares of argenx by 19.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 9,074 shares of the company’s stock worth $872,000 after acquiring an additional 1,446 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of argenx by 46.6% in the fourth quarter. Geode Capital Management LLC now owns 14,630 shares of the company’s stock worth $1,405,000 after acquiring an additional 4,649 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of argenx by 23.1% in the fourth quarter. Bank of America Corp DE now owns 10,247 shares of the company’s stock worth $984,000 after acquiring an additional 1,925 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of argenx by 0.3% in the fourth quarter. FMR LLC now owns 3,487,052 shares of the company’s stock worth $335,001,000 after acquiring an additional 12,003 shares in the last quarter. Institutional investors and hedge funds own 68.02% of the company’s stock.

NASDAQ:ARGX traded down $1.97 on Friday, hitting $142.61. 125,354 shares of the company’s stock were exchanged, compared to its average volume of 122,932. The business has a 50-day simple moving average of $140.44. argenx has a 52 week low of $63.81 and a 52 week high of $150.92. The stock has a market capitalization of $4.65 billion, a P/E ratio of -60.69 and a beta of 1.18.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Key terms to understand channel trading

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.